Clinical Trials Sponsored by Closter Pharma

Total 8525 results

UCB Pharma

Completed

SPM 927 (400mg/Day and 600mg/Day) as Adjunctive Therapy in Subjects With Partial Seizures With or Without Secondary Generalization

Epilepsy
LEO Pharma

Completed

Safety and Dose Finding Study of New Vehicle Formulations Containing Ingenol Mebutate to Treat Actinic Keratosis on the Forearm

Actinic Keratosis

Australia
UCB Pharma

Completed

Rotigotine Effect on All-day Functioning and Quality of Life in Subjects With Moderate to Severe Restless Legs Syndrome (RLS) (RESTORE)

Restless Legs Syndrome

United States
UCB Pharma

Completed

Facial Thermography Study of Levocetirizine Versus Cetirizine

Anti-allergic Agents
LEO Pharma

Completed

Study on Thrombosis Therapy in German Cancer Patients

Cancer | Deep Vein Thrombosis | Pulmonary Embolism

Germany
LEO Pharma

Completed

Long-Term Innohep® Treatment Versus a Vitamin K Antagonist (Warfarin) for the Treatment of Venous Thromboembolism (VTE) in Cancer

Venous Thromboembolism

Canada
UCB Pharma

Withdrawn

Study of Epratuzumab in Systemic Lupus Erythematosus

Systemic Lupus Erythematosus

United States, France, United Kingdom, Spain, Belgium, Netherlands, Canada, Brazil, Germany, Hungary, Czech Republic, Italy, Slovakia
UCB Pharma

Completed

Placebo-controlled Study in Patients With Parkinson's Disease to Evaluate the Effect of Rotigotine on Non-motor Symptoms

Idiopathic Parkinson's Disease

Germany, Austria, Belgium, Bulgaria, Czech Republic, France, Hungary, Italy, Romania, Slovakia, Spain, Switzerland
Advanz Pharma

Terminated

A Phase 3b Study of Vernakalant Injection in Patients With Recent Onset Symptomatic Atrial Fibrillation (AF)(MK-6621-045) (ACT V)

Atrial Fibrillation
UCB Pharma

Completed

Follow-up of Rheumatoid Arthritis (RA) Moderate to Low Disease Activity Study (CERTAIN 2)

Rheumatoid Arthritis

Poland, Germany, Austria, France, Italy
UCB Pharma

Completed

Crossover Study of Neuropsychological Effects of Lacosamide and Carbamazepine Immediate Release in Healthy Subjects

Healthy

United States
LEO Pharma

Completed

A Plaque Test Study With LEO 35299 in Psoriasis Vulgaris

Psoriasis Vulgaris

France
Vifor Pharma

Completed

Ferric Carboxymaltose in Subjects With Functional Iron Deficiency Undergoing Chemotherapy (FID-CHEMO)

Iron-Deficiency Anemia

Germany, Sweden
UCB Pharma

Completed

To Evaluate the Efficacy and Safety of Levocetirizine Versus Loratadine for Treatment of Seasonal Allergic Rhinitis

Rhinitis | Allergic | Seasonal
UCB Pharma

Completed

Efficacy and Safety of Piracetam Taken for 12 Months in Subjects Suffering From Mild Cognitive Impairment (MCI)

Memory Disorders
UCB Pharma

Completed

LEADER (LEvocetirizine And DEsloratadine in Allergic Rhinitis)

Rhinitis, Allergic, Perennial
UCB Pharma

Completed

Efficacy and Safety of Levocetirizine Versus Loratadine for the Treatment of Perennial Allergic Rhinitis

Rhinitis | Allergic | Perennial
UCB Pharma

Completed

Efficacy and Safety of Levocetirizine 8 Weeks Prior and After the Onset of the Grass Pollen Season in Subjects With SAR

Rhinitis, Allergic, Seasonal
UCB Pharma

Completed

Study to Compare the Efficacy and Safety Between Levocetirizine and Loratadine for Chronic Idiopathic Urticaria

Urticaria
LEO Pharma

Completed

LEO 27847 - Single Dose Bioavailability Study of Oral Solution Versus Tablet in Healthy Subjects

Healthy

United Kingdom
UCB Pharma

Completed

Caregivers' and Physicians' Treatment Preference in Parkinson Patients Treated With Neupro® Requiring Caregiver Support (CARE-ACT)

Idiopathic Parkinson's Disease

Germany
UCB Pharma

Completed

Monotherapy With Levetiracetam in Newly Diagnosed Patients Suffering From Epilepsy

Generalized Epilepsy
UCB Pharma

Completed

Study to Evaluate the Safety and Efficacy of Levetiracetam in Patients Suffering From Idiopathic Generalized Epilepsy With Primary Generalized Tonic-clonic Seizures

Generalized Convulsive Epilepsy
UCB Pharma

Completed

Monotherapy With Levetiracetam or Carbamazepine in Patients Suffering From Epilepsy.

Epilepsy, Tonic-clonic
UCB Pharma

Completed

Determine Effects of Adjunctive Levetiracetam on Sleep Architecture in Adults With Partial Onset Epilepsy.

Epilepsy, Partial
UCB Pharma

Completed

A Phase IV-Pharmacovigilance Study of Keppra Greece - S.K.A.T.E.: Safety of Keppra as Adjunctive Therapy in Epilepsy

Epilepsy
UCB Pharma

Completed

Trial to Evaluate the Safety and Efficacy of Keppra After Conversion to Mono-therapy in Subjects With Partial Epilepsy

Epilepsy
UCB Pharma

Completed

Pharmacokinetic Study of Levetiracetam in Epileptic Pediatric Subjects Ranging in Age From 1 Month to Less Than 4 Years Old

Epilepsy
UCB Pharma

Completed

S.K.A.T.E.: Safety of Keppra as Adjunctive Therapy in Epilepsy

Epilepsy
UCB Pharma

Completed

Pharmacovigilance Study of Keppra. SPAIN - SKATE : Safety of Keppra as Adjunctive Therapy in Epilepsy

Epilepsy, Partial
LEO Pharma

Completed

LEO 27847 - A Study in Healthy Male Subjects

Healthy

United Kingdom
LEO Pharma

Completed

LEO 32731 - A Study in Healthy Male Subjects

Healthy Subjects

United Kingdom
LEO Pharma

Completed

A Psoriasis Plaque Test on LEO 27989 Ointment and Calcipotriol Plus LEO 27989 Ointment in Patients With Psoriasis Vulgaris

Psoriasis Vulgaris

France
LEO Pharma

Completed

A Psoriasis Plaque Test Comparing Eight Different Formulations of Vitamin D Analogues for the Treatment of Psoriasis

Psoriasis Vulgaris

France
Clavis Pharma

Completed

Study of Elacytarabine Versus Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia (AML) (CLAVELA)

Acute Myeloid Leukemia (AML)

United States, Spain, France, Ireland, United Kingdom, Australia, Belgium, Canada, Germany, Italy, Norway, Poland, Romania
Evgen Pharma

Completed

Sulforadex in Healthy Volunteers SAD

Stage, Prostate Cancer

United Kingdom
UCB Pharma

Completed

A Safety and Efficacy Follow-up Study With Levetiracetam in Children (4-17 Years Old) Suffering From Absence Seizures

Absence Seizures
LEO Pharma

Completed

An Exploratory Psoriasis Plaque Test Study With Different Dose Combinations of Calcipotriol Plus Betamethasone Dipropionate in the Daivobet® Gel Vehicle in Psoriasis Vulgaris

Psoriasis Vulgaris

France
LEO Pharma

Completed

Safety and Tolerability of Different Concentrations of an Ingenol Derivative Field Therapy in the Treatment of Actinic Keratosis

Actinic Keratosis

Australia
LEO Pharma

Completed

Safety, Tolerability and Pharmacokinetic Study in Healthy Subjects by Dermal Application of a LEO 29102

Atopic Dermatitis

United Kingdom
Vifor Pharma

Completed

A Drug-Drug Interaction Study of Losartan and PA21

Drug Interaction Potentiation

United States
UCB Pharma

Completed

Non-interventional Study (NIS) in Patients With Restless Legs Syndrome in Daily Practise (RLS-Practise)

Idiopathic Restless Legs Syndrome

Germany
UCB Pharma

Completed

A Randomized, Double-blind, Pharmacokinetics Study to Assess Safety, Tolerability of Levetiracetam 45 Minutes Intravenous Infusion During 4 Days of Bid Dosing in Chinese Healthy Volunteers

Human Volunteers

China
UCB Pharma

Completed

Open-label Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus Patients With Active Disease

Systemic Lupus Erythematosus

United States, Poland, Spain, Belgium, India, Ukraine, Brazil, United Kingdom, Hungary, Lithuania, Hong Kong
UCB Pharma

Withdrawn

Evaluate Efficacy of Certolizumab in Crohn's Patients With Draining Fistulas

Crohn Disease
UCB Pharma

Completed

Clinical Study in Healthy Volunteers to Investigate the Neurocognitive Effects of a New Antiepileptic Drug: Brivaracetam

Epilepsy

United States
UCB Pharma

Completed

Evaluation of Safety of Levocetirizine in Routine Clinical Practice-non- Interventional Study

Rhinitis Allergic, Persistent

United States
UCB Pharma

Withdrawn

A Trial Evaluating Safety of Chronic Therapy With Certolizumab Pegol in Crohn's Disease

Crohn's Disease
UCB Pharma

Withdrawn

A Study to Evaluate the Efficacy and Safety of Seletracetam in Adult Patients With Refractory Partial Onset Seizures

Epilepsies, Partial
UCB Pharma

Completed

Cross Sectional Study to Evaluate the Acceptability of Oral Solution of Levetiracetam

Epilepsy

Spain

3

Subscribe